Using fecal immunochemical tubes for the analysis of gut microbiome has potential to improve colorectal cancer screening
BackgroundColorectal cancer (CRC) is an important and challenging public health problem which successful treatment depends on the early detection of the disease. Recently, colorectal cancer specific microbiome signatures have been proposed as an additional marker for CRC detection. A desirable aim would be the possibility to analyze microbiome from the fecal samples collected during CRC screening programs into FIT tubes for fecal occult blood testing. MethodsWe investigated the impact of the Fecal Immunohistochemical Test (FIT) and stabilization buffer on the microbial community structure in stool samples from 30 volunteers and compared their communities to fresh-frozen samples highlighting also the previously published cancer-specific communities. Altogether 214 samples were analyzed including positive and negative controls using 16S rRNA gene sequencing. ResultsThe variation between individuals is greater than the differences introduced by collection strategy. The vast majority of the genera are stable for up to 7 days. None of the changes observed between fresh frozen samples and FIT tubes are related to previously shown colorectal-cancer specific bacteria. ConclusionsOverall, our results show that FIT tubes can be used for profiling the gut microbiota in colorectal cancer screening programs as the community is similar to fresh frozen samples and stable at least for 7 days. ImpactSample material from FIT tubes could be used in addition to fecal immunochemical tests for future investigations into the role of gut microbiota in colorectal cancer screening programs circumventing the need to collect additional samples and possibly improving the sensitivity of FIT.